PTOiAIA/M (OB-12)
`Approved for use through 01:!31l2'014. OMB 0651-0032
`US. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1 995, no persons are required to respond to a collection ofin'forrnation unless it contains 'a valid OMB control number.
`
`
`Attorney Docket Number GWLG-O‘l YUS-ClP
`
`Application Data Sheet 37 CFR 1.76
`
`Application Number
`
`
`
`Title Of Invention
`
`METHOD FOR DIAGNOSING AND MONITORING INFLAMMATORY DISEASE PROGRESSION
`
`
`The application data sheet ispan of'the provisional or nonprovisional application for which it is being submitted. The following form contains the
`bibliographic data arranged in a format specified by theUnited States Patent and Trademark Office as outlined in 37 CFR 1.76.
`This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the
`document may be printed and included in a paper filed application.
`
`
`
`
`
`Secrecy Order 37 CFR 5.2
`,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
`
`Portions or all of the‘ application associated with this Application Data Sheet may fall under a secrecy Order pursuant to.
`
`
`
`37 CFR 5.2 (Paper filers only. Applications that fall underiSecrecy Order may not be filed electronically.)
`
`
`Prefix Given Name
`Middle Name
`Family Name
`Suffix-
`
`Inventor Information:
`
`
` Legal Name
`
`
`
`
`vi Warren
`Foster
`Residence Information (Select One) 0 US Residency @ Non US Residency 0 Active US Military Service
`
`
`
`
`7 ‘Country of Residence iAncasterCity CA
`
`v
`
`
`Mailing Address of Inventor:
`
`
`Address 1
`13 Landscapes Trail
`‘ Address: ‘
`
`ON
`‘ StatelProvince
`City
`i Ancaster
`Postal .Code
`:Countryi
`CA
`LQK 0A1
`
`Inventor
`2
`‘ Legal Name
`
`
`
`
`
`
`Prefix Given Name
`v Jocelyn
`Residence Information (Seléct One) 0 US Residency
`
`Middle Name
`
`i Suffix
`Family Name
`i
`.v
`Wessels
`(a) Non US Residency 0 Active US Military Service
`
`City
`Guelph
`Country of Residence
`i
`CA
`
`
`
`Mailing Address of Inventor:
`
`Address 1
`42 Waxwing Crescent
`
`
`
`
`
`
`Address 2
`I Guelph
`City
`Postal Code
`
`L88 4K1
`
`StatelProvince
`Co‘untr'yi
`CA
`
`i ON
`
`,,,I,fl!§flt9[,,,,,,,§,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
`Legal Name
`
`
`
`EFS Web'2;2.4
`
`

`

`Application Data Sheet 37 CFR 1.76
`
`PTOIAIAJ'14 (OB-12)
`Approved for use through 011312014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1 995, no persons are required to respond to a collection ofinformation unless it contains a valid OMB control number.
`
`GWLG-017US-CIP
` Attorney Docket Number
`
`
`I Application Number
`Title of Invention METHOD FOR DIAGNOSING AND MONITORING INFLAMIVIATORY DISEASE PROGRESSION
`
`
`
`
`
`
`
`Prefix Given Name
`Middle Name
`Suffix
`Family Name
`
`v Sanjay
`Agarwal
`
`0 Non US Residency
`Residence Information (Select One) ©7 US Residency
`0 Active US Military Service
`
`
`
`
`City
`Rancho Santa Fe
`State/Province
`CA
`Country of Residencé
`US
`
`
`Mailing Address of Inventor:
`
`‘ Address 1
`PO Box 3831
`
`
`
`
`
`
`
`
`
`City
`Rancho Santa Fe
`StatelProvince
`CA
`
`
`
`CountryI
`Postal Code
`92067
`US
`
`Inventor
`4
`
`Legal Name
`
`Prefix Given Name
`Middle Name
`Family Name
`Suffix
`
`Address 2
`
`' Leyla:
`
`Edema!
`
`'
`
`
`
`
`
`Residence Information (Select One) 0 US Residency © Non US Residency 0 Active US Military Service
`
`City
`Oakville
`‘Country of Residence
`i
`CA
`
`
`Mailing Address of Inventor:
`
`Address 1
`EELVfltflngtorfi’lace
`Address 2
`
`
`
`
`
`City
`Oahile
`StateIProvince
`fl
`
`
`
`Postal Code
`gig/g
`Countryi
`g1
`Inventor
`Inventors Must Be Listed - Additional
`Information blocks may be
`All
`
`generated within this form by selecting the Add button.
`
`
`Correspondence Information:
`
`Enter either Customer Number or complete the Correspondence Information section below.
`For further information see 37 CFR 1.33(a).
`
`
`
`An Address is being provided for the correspondence Information of this application.
`
`
`
`Customer Number
`88993
`
`
` Email Address
`
`
` philip.z hang@ mzwiplaw. com
`
`
`
`EFS Web 2.2.4
`
`

`

`PTOiAIA/M (OB-12)
`Approved for use through 01:!31l2'014, OMB 0651-0032
`us. Patent and Trademark Office; us. DEPARTMENT OF COMMERCE
`Under the PaperworkReduction Act of 1 995, no per-sons are required to respond to a coilectioneofinfiorma-tion unless it contains a valid OMB control number.
`
`
`i Attorney Docket Number
`Application Data Sheet 37.CFR 1.76 .
`g
`.,
`_ g
`i Application Number
`
`GWLG-017US-CIP
`
`
`
`
`
`METHOD FOR DIAGNDSING AND MONITORING INFLAMMATORY DISEASE PROGRESSION
`
`Title Of Invention
`
`Application information:
`
`Title ‘of the Invention
`‘ METHOD FOR DIAGNOSING AND MONITORING lNFLAMMATORY DISEASE PROGRESSION
`
`
`
`
` Attorney Docket Number GWLG—Oi TUS—CIP Small Entity Status Claimed E
`
`
`
`Application Type
`Nonprovisionai
`v
`
`
`
`
`
`Subject Matter
`Utility
`v.
`
`
`Suggested Class (if any)
`Sub Ciass(if any)
`‘ Suggested Technology Center (if any) ‘
`
`
`
`i 21Total Number of Drawing Sheets (if any) Suggested Figure for Publication (if any)
`
`Publication Information:
`
`
`
`
`
`
`
`
`
`
`
`
`
`Request Early Publication ‘(Fee required at time of Request 37 CFR 1.219)
`
`
`
`
`
`Request Not to Publish. ihereby request that the attached application not be published under
`35 USC. 122(b) and certify that the invention disclosed in the attached application has not and will not be the
`subject of an application filed in another country,~or under a multilateral international agreement, that requires
`
`publication at eighteen months after filing.
`
`Representative information:
`
`Representative information should be. provided for all practitioners having a power of attorney in the application. Providing
`this information in the Application Data Sheet does not constitute a power of attorney in the application {see 37'CFR 1.32).
`Either enter Customer Number or complete the Representative Name section below.
`if both sections are completed the customer
`Number will be used for the Representative Information during processing.
`
`
`
`
`
`
` PleasevSeiect One: CO} Customer Number i 0 US Patent Practitioner i 0 Limited Recognition (37 CFR 11.9).
`Customer Number
`88993
`
`
`
`Domestic Benefithationai' Stage information:
`
`Thissection allows for the applicant to either claim benefit under 35 USC. 11:9(e), 1'20, 121: or 365(0) or indicate
`National Stage entry from a PCT application. Providing this information in the application data sheet constitutes the
`
`specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
`Prior Application Status
`Pending
`v
`.
`
`
`1
`
`
`Application Number
`Continuity Type
`Prior Application Number
`Filing Date (WW-MM-DD)
`
`Continuation in part of
`v 15094086
`x 2016-04-08
`
`
`
`Prior Application Status
`
`Expired
`
`v
`
`Application Number
`
`Continuity Type,
`
`Prior Application Number
`
`Filing Date (WW-.Mivi-DD)
`
`15094086
`
`Continuation in part of
`
`v PCTICA2014/OOOT42
`
`2014-10-10
`
`
`1
`Prior Application Status
`EFS Web'2;2.4
`
`

`

`PTOfAIA/M (OB-12)
`Approved for use through 01:!31l2'014, OMB 0651-0032
`us. Patent and Trademark Office; us. DEPARTMENT OF COMMERCE
`Under the PaperworkReduction Act of 1 995, no persons are required to respond to a collectioncofinfiorma-tion unless it contains a valid OMB control number.
`
`
`
`Application Data Sheet 37 CFR 1 76 I Attorney Docket Number
`_ GWLG-017US-CIP
`'
`I
`I
`I Application Number
`
`
`
`
`
`Title Of Invention
`
`MEl'l-IOD FOR DIAGNDSING AND MONITORING INFLAMMATORY DISEASE PROGRESSION
`
`Application Number
`
`I
`
`Continuity Type
`
`I
`
`Prior Application Number
`
`Filing Date (YYW—MM-DD)
`
`PCTI'CAQO‘I 42000742
`
`non provisional of
`
`v 61889085
`
`201 31-10-10
`
`Additional Domestic Benefithational Stage Data may be generated within this form
`
`byselecting the Add button.
`
`Foreign Priority Information:
`
`This section allows for the applicant to claim benefit of foreign priority and to identify any prior foreign application for which priority is
`not claimed. Providing this information in the application data sheet constitutes the claim for priority as required by 35 'U.S.C. 119(b)
`and 37 CFR 1.355(a).
`
`Application Number
`
`CountryE
`
`
`I
`Filing Date (YWY‘M M‘DD)
`Priority Claimed
`
`@ Yes O No
`
`
`
`
`
`
`
`
`
`
`
`
`
`Additional Foreign'Priority Data may be generated within this form'by selecting the
`
`Add button.
`
`
`Authorization to. Permit Access:
`
`E Authorization to Permit Access to the Instant Application by the Participating Offices
`If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO):
`the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (-WIPO),
`and any other intellectual property offices in Which a foreign application claiming priority to the instant patent application
`is filed access to the instant patent application. See 37 CFR 114(0) and (h). This box should not be checked if the. applicant
`does not wish the EPO: JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority
`to the instant patent application is filed to have access to the instant patent application.
`
`In accordance with 37‘ CFR 'l_.‘l4(h)(3)., access will be provided to a copy of the instant patent application with respect
`to: 1) the instant patent application-as-filed; 2) any foreign application to which the instant patent application
`claims priority under 35 U.S.C. 119(a)-(d) its copy of the foreign application that satisfies the certified copy requirement of
`37 CFR 1.55 has been filed in the instant patent application; and 3) any US. application-as-filed from which benefit is
`sought in the instant patent application.
`
`in accordance with 37 CFR 1314(0), access maybe provided to. information concerning the date of filing this Authorization.
`
`
`
`Applicant Information:
`
`
`
`
`
`
`Providing assignment information in this section does. not substitute for compliance with any requirement of part 3 of Title 37' of CFR
`to have an assignment recorded by the Office.
`
`EFS Web'2.’2.4
`
`

`

`
`
`PTOiAIA/M (OB-12)
`Approved for use through 01:!31l2'014, OMB 0651-0032
`us. Patent and Trademark Office; us. DEPARTMENT OF COMMERCE
`
`Under the PaperworkReduction Act of 1 995, no per-sons are required to respond to a collectionpfinfiorma-tion unless it contains a valid OMB control number.
`
`I Attorney Docket Number
`Application Data Sheet 37.CFR 1.76 .
`y
`.,
`_ y
`1 Application Number
`
`GWLG-Ot'lUS-CIP
`
`Title Of Invention
`
`MEl'l-IOD FOR DIAGNDSING AND MONITORING INFLAMMATORY DISEASE PROGRESSION
`
`
`
`
`
`
`
`Applicant
`1
`if the applicant is the inventor (or the remaining jointinventor or inventors under 37' CFR 1.45). this section should not be completed.
`The information to be provided in thissectio‘n is the name and address of the legal representative who is the applicant under 37 CFR
`1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person
`who'otherwise shows sufficient proprietary interest in the matter who is'the applicant under 37 CFR 1.46. If the applicant is an
`applicant under 37'CFR 1.46 (assignee, person to Whom the inventor isobligated tosassign, or person who otherwise shows sufficient
`proprietary interest) together With one or more joint inventors, then the joint inventor or inVentors who are also the applicant should be
`identified in thissection.
`
`O 0 Legal Representative under 35 USO 117 Assignee
`
`
`
`
`
`
`Cg)
`Person to Whom the inventor is obligated to assign.
`(3
`Person who shOWs sufficient proprietary interest
`lf appliCaht is the legal representativ-e: indicate the authority to file the patent application, the inventor is:
`
`
`'I
`
`
`Name of the Deceased or Legally ln‘capacitated Inventor :‘
`
`If the Assignee is an Organization check here.
`53
`
`
`organization Name
`MCMASTER UNIVERSITY
`
`
`Mailing Address Information:
`
`Address 1
`175 Longwood Road South
`
`AddressZ
`"sagas"’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’
`
`Additional Applicant Data may be generated within this form by selecting the Add button.
`
`
`Signature:
`
`NOTE: This form must be Signedin accordance with 37 CFR 1.33,. see 37 CFR 1.4 for signature requirements and
`
`certifications
`
`
`
`
`
`201 7-09-12 Signature IYin P. Zhanig 44.372! ‘ Date (YYYY-MM-DD)
`
`443??
`Zhang
`LastName
`1 Registration Number
`Yin Philip
`First Name
`
`
`
`
`Additional Signature may be generated within this form by selecting the, Add button.
`
`EFS Web'2.’2.4
`
`
`
`
`
`
`City
`Hamilton
`StatelP r‘ovince
`ON
`Country} i CA
`Postal Code
`LSP 0A1
`Phone Number
`Fax Number
`
`Email Addresa
`
`
`
`
`

`

`PTOiAIA/M (OB-12)
`Approved for use through 01:!311’2'014, OMB 0651-0032
`us. Patent and Trademark Office; us. DEPARTMENT OF COMMERCE
`Under the PaperworkReduction Act of 1 995, no per-sons are required to respond to a collectionofinfiormation unless it contains a valid OMB control number.
`
`
`
`Application Data Sheet 37 CFR 1 76 I Attorney Docket Number
`_ GWLG-017US-CIP
`
`'
`I
`I
`I Application Number
`
`
`METHOD FOR DIAGNDSING AND MONITORING INFLAMMATORY DISEASE PROGRESSION
`
`Title Of Invention
`
`This collection of information is required by 37' CFR 176. Theinformation is required to obtain or retain a benefit by the public which
`is to file'(andv by the USPTO to process) an application. Confidentiality is governed by 35 USS. ‘122 and 37 CFR- 1.14., This
`collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data
`sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amountof time you require to
`complete this form andlor suggestions for reducing this burden, should be sent'to theChief Information Officer, US. Patent and
`Trademark. Office, US. Department of Commerce, PO. Box 1450, Alexandria, VA 22313-1450., DO NOT SEND FEES QR
`COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P;Q,. Box 1450., Alexandria, VA 2231 3~1 45-0.
`
`EFS Web'2.’2.4
`
`

`

`Privacy Act Statement
`
`
`
`
`
`The Privacy'Act of 1974 (P.L. Bit-5%) requires that you be given certain information in connection with your submission of the attached form related to
`a patent application or patent. Accordingly, pursuantto‘the requirements of the Act, please be advised‘that:
`(1') the-general authority for the collection
`of this information is 35 U.S'.C. 2‘(b)'(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is
`used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent.
`if you do not
`furnish the requested information, the US. Patent and Trademarthfice may not be able to process and/or examine your submission, which may-
`result in termination of proceedings or abandonment of the application-or expiration ofthe patent.
`
`The information provided by you in this form will be subject to the‘following routine uses:
`
`1.
`
`The information on this form will be treated confidentiaiiy to the extent allowed under the Freedom of information Act (5 U.S.C. 552)
`and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine
`Whether the Freedom of information Act requires'disciosure of these records;
`
`A record from thissystem of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate,.or
`administrative tribunal, including-disclosures to opposing counsel in the course of settlement negotiations.
`
`A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting, a request involvingan
`individual, to whom the. record pertains, when the individual has requested assistance from the Member with respect to thesu'bject matter of
`the record.
`
`A record in this system of records may be disclosed, as a routine. use, to a contractor of the Agency having need forthe information in
`order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as
`amended, pursuant to 5 U.S.C. 552atm).
`
`A record related to an international Application flied under'the Patent Cooperation Treaty in this system of records may be disclosed,
`as-a routine use, tothe International Bureau of the World intellectual Property Organization, pursuantto the Patent Cooperation Treaty.
`
`A record in this system of records may be disclosed, as a'routine use, to an other federal agency fer purposes of National Security
`review-(35 U.S.C. 181);and for review pursuant to the Atomic Energy Act (42 U.S.C. 21B_(c)).
`
`A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisiher designee,
`during an inspection of records conducted by GSA as part of that agency's responsibilityto recommend improvements- in records
`management practices and programs, under authority'of 44 USC. 2904 and 2906‘. Such disclosure shall be madein accordance with the
`GSA regulations governing inspection of records for this Purpose, and any other relevant (i.‘e., GSA or Comm‘erceidirective. Such
`disclosure shall not be used to make determinations about individuals.
`
`A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant
`to 35 U,S.C. 12203) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of.37
`CFR 1.14, as a routine use, to the public ifthe record was filed in an application which becameabandoned or in which the proceedings were
`terminated and which application is referenced by'either a published application, an application open to'publi‘c inspections or an issued
`patent.
`
`A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the
`USPTO becomes aware of a violation or potential violation of law or regulation.
`
`
`
`EFS Web'2.’2.4
`
`
`
`